ES2093562A1 - Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. - Google Patents

Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Info

Publication number
ES2093562A1
ES2093562A1 ES09501035A ES9501035A ES2093562A1 ES 2093562 A1 ES2093562 A1 ES 2093562A1 ES 09501035 A ES09501035 A ES 09501035A ES 9501035 A ES9501035 A ES 9501035A ES 2093562 A1 ES2093562 A1 ES 2093562A1
Authority
ES
Spain
Prior art keywords
formation
colloidal systems
stabilization
systems
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09501035A
Other languages
English (en)
Other versions
ES2093562B1 (es
Inventor
Fernandez Maria Jose Alonso
Salve Pilar Calvo
Lopez Carmen Remunan
Jato Jose Luis Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09501035A priority Critical patent/ES2093562B1/es
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Priority to CA002195881A priority patent/CA2195881C/en
Priority to DK96914215T priority patent/DK0771566T3/da
Priority to US08/776,507 priority patent/US5843509A/en
Priority to DE69634927T priority patent/DE69634927T2/de
Priority to PCT/ES1996/000116 priority patent/WO1996037232A1/es
Priority to PT96914215T priority patent/PT771566E/pt
Priority to AT96914215T priority patent/ATE330636T1/de
Priority to EP96914215A priority patent/EP0771566B1/en
Publication of ES2093562A1 publication Critical patent/ES2093562A1/es
Application granted granted Critical
Publication of ES2093562B1 publication Critical patent/ES2093562B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTABILIZACION DE SISTEMAS COLOIDALES MEDIANTE FORMACION DE COMPLEJOS IONICOS LIPIDO-POLISACARIDO. DESARROLLO DE UN PROCEDIMIENTO PARA PREPARAR SISTEMAS COLOIDALES QUE COMPRENDE INCORPORAR EN EL UNA COMBINACION DE UN AMINOPOLISACARIDO SOLUBLE EN AGUA Y DE CARGA POSITIVA Y UN FOSFOLIPIDO DE CARGA NEGATIVA. LOS SISTEMAS COLOIDALES (DENTRO DE LOS CUALES SE INCLUYEN NANOEMULSIONES, NANOCAPSULAS Y NANOPARTICULAS POLIMERICAS) SE ESTABILIZAN MEDIANTE LA FORMACION DE UN COMPLEJO IONICO, A NIVEL INTERFACIAL, CONSTITUIDO POR EL AMINOPOLISACARIDO Y EL FOSFOLIPIDO. LOS SISTEMAS COLOIDALES SE CARACTERIZAN POR PRESENTAR UN TAMAÑO DE PARTICULA INTERIOR A 1 MIM, UNA CARGA ELECTRICA POSITIVA Y UNA ESTABILIDAD EXCEPCIONAL DURANTE EL ALMACENAMIENTO. SON LIOFILIZABLES, LO QUE PERMITE SU CONSERVACION EN SECO Y SU POSTERIOR REDISPERSION MANTENIENDO LAS CARACTERISTICAS ORIGINALES DEL SISTEMA. OFRECEN INTERES COMO FORMAS FARMACEUTICAS PARA LA ADMINISTRACION DE MEDICAMENTOS POR LAS VIAS ORAL, TRANSDERMICA, TOPICA,OCULAR, NASAL Y VAGINAL. ADEMAS OFRECEN INTERES COMO FORMAS DE USO COSMETICO.
ES09501035A 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. Expired - Fee Related ES2093562B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES09501035A ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
DK96914215T DK0771566T3 (da) 1995-05-26 1996-05-24 Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser
US08/776,507 US5843509A (en) 1995-05-26 1996-05-24 Stabilization of colloidal systems through the formation of lipid-polyssacharide complexes
DE69634927T DE69634927T2 (de) 1995-05-26 1996-05-24 Stabilisation von kolloidalen systemen durch die bildung von ionischen lipid-polysaccharid-komplexen
CA002195881A CA2195881C (en) 1995-05-26 1996-05-24 Stabilization of colloidal systems through the formation of lipid-polysaccharide complexes
PCT/ES1996/000116 WO1996037232A1 (es) 1995-05-26 1996-05-24 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido
PT96914215T PT771566E (pt) 1995-05-26 1996-05-24 Estabilizacao de sistemas coloidais pela formacao de complexos ionicos lipido-polissacarido
AT96914215T ATE330636T1 (de) 1995-05-26 1996-05-24 Stabilisation von kolloidalen systemen durch die bildung von ionischen lipid-polysaccharid- komplexen
EP96914215A EP0771566B1 (en) 1995-05-26 1996-05-24 Stabilization of colloidal systems by the formation of ionic lipid-polysaccharide complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09501035A ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Publications (2)

Publication Number Publication Date
ES2093562A1 true ES2093562A1 (es) 1996-12-16
ES2093562B1 ES2093562B1 (es) 1997-07-01

Family

ID=8290513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09501035A Expired - Fee Related ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Country Status (9)

Country Link
US (1) US5843509A (es)
EP (1) EP0771566B1 (es)
AT (1) ATE330636T1 (es)
CA (1) CA2195881C (es)
DE (1) DE69634927T2 (es)
DK (1) DK0771566T3 (es)
ES (1) ES2093562B1 (es)
PT (1) PT771566E (es)
WO (1) WO1996037232A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197836A1 (es) * 2002-06-28 2004-01-01 Consejo Superior Investigacion Procedimiento para la preparacion de nano-emulsiones de tipo agua en aceite (w/o) por metodos de emulsificacion de condensacion.
WO2018146365A1 (es) 2017-02-09 2018-08-16 Universidade De Santiago De Compostela Particulas purificadas de polen y su uso para administrar nanosistemas

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
FR2760641B1 (fr) * 1997-03-13 2000-08-18 Oreal Emulsion huile-dans-eau stable, son procede de fabrication et son utilisation dans les domaines cosmetique et dermatologique
DE19733625A1 (de) * 1997-07-28 1999-02-04 Lancaster Group Gmbh Dekorative kosmetische O/W-Emulsion
KR19990058599A (ko) * 1997-12-30 1999-07-15 손경식 이중 캡슐을 함유하는 화장료 조성물
DE19826503A1 (de) * 1998-06-13 1999-12-16 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Chitosan und Phospholipiden
ATE293895T1 (de) * 1999-10-29 2005-05-15 Hunza Di Pistolesi Elvira E C Faserige lipo-ernährungskomplexe und diese enthaltende zusammensetzungen
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
ATE281235T1 (de) * 2000-02-23 2004-11-15 Henkel Kgaa Wasch- oder reinigungsmittel mit komponenten in form von mikro- und/oder nanokapseln
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
MXPA03002851A (es) 2000-10-02 2003-07-14 Kimberly Clark Co Tintas con base de nanoparticula y los metodos para hacer las mismas.
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
US20020197210A1 (en) * 2001-03-08 2002-12-26 Bednarski Mark David Stabilized therapeutic and imaging agents
US6673263B2 (en) 2001-07-26 2004-01-06 Ppg Industries Ohio, Inc. Compositions incorporating chitosan for paint detackification
US20040000329A1 (en) * 2001-07-26 2004-01-01 Albu Michael L. Compositions and methods for paint overspray removal processes
AU2002332020A1 (en) * 2001-10-03 2003-04-14 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20030176310A1 (en) * 2002-03-15 2003-09-18 Huang Robert Y.M. Chitosan/anionic surfactant complex membrane
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
AU2004203700B2 (en) 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1656192B1 (en) * 2003-08-20 2015-08-26 Merck Patent GmbH Methods for extraction and concentration of hydrophilic compounds from hydrophobic liquid matrices
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
KR20060097020A (ko) * 2003-10-31 2006-09-13 테바 파마슈티컬 인더스트리즈 리미티드 약물 전달용 나노입자
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US20060003956A1 (en) * 2004-03-03 2006-01-05 Casadome David O Materials and methods for the derepression of the E-cadherin promoter
WO2005087221A1 (en) * 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
CN1311867C (zh) * 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂
ES2259914B1 (es) * 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
DK1834635T3 (da) * 2006-03-13 2011-10-24 Advancell Advanced In Vitro Cell Technologies S A Stabile nanokapselsystemer til administrtion af aktive molekyler
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8778400B2 (en) * 2008-04-21 2014-07-15 University Of South Australia Nanoparticle-stabilized capsule formulation for treatment of inflammation
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
MX340134B (es) 2009-07-09 2016-06-28 Oshadi Drug Administration Ltd Composiciones portadoras de matriz, métodos y usos.
EP2361509A1 (en) 2010-02-15 2011-08-31 Nestec S.A. Liquid-filled protein-phosphatidic acid capsule dispersions
EP2364600A1 (en) 2010-02-18 2011-09-14 Nestec S.A. Liquid-filled chitosan-anionic liposoluble capsule dispsersions
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US9326980B2 (en) * 2013-07-21 2016-05-03 Kimia Zist Parsian (Kzp) Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine
US9351932B2 (en) * 2014-07-21 2016-05-31 Kimia Zist Parsian (Kzp) Method and system for synthesizing nanocarrier based long acting drug delivery system for methadone
PL229276B1 (pl) 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US11883401B2 (en) 2019-01-08 2024-01-30 Duke University Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
CA3126322A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
MX2021013356A (es) 2019-05-03 2022-03-11 Singapore Health Serv Pte Ltd Tratamiento y prevencion de enfermedades metabolicas.
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
EP4376948A1 (en) 2021-07-26 2024-06-05 Boehringer Ingelheim International GmbH Treatment and prevention of alcoholic liver disease
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486959A1 (en) * 1990-11-22 1992-05-27 Vectorpharma International S.P.A. Pharmaceutical composition of microparticles with controlled release and process of preparing it

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486959A1 (en) * 1990-11-22 1992-05-27 Vectorpharma International S.P.A. Pharmaceutical composition of microparticles with controlled release and process of preparing it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F€LDT, P. et al., "Stabilization by chitosan of soybean oil emulsions coated with phospholipid and glycocholic acid", 1993, Colloids and surfaces A: physicochemical and engineering aspects", vol. 71, pp.:187-195. * todo el documento * *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197836A1 (es) * 2002-06-28 2004-01-01 Consejo Superior Investigacion Procedimiento para la preparacion de nano-emulsiones de tipo agua en aceite (w/o) por metodos de emulsificacion de condensacion.
WO2018146365A1 (es) 2017-02-09 2018-08-16 Universidade De Santiago De Compostela Particulas purificadas de polen y su uso para administrar nanosistemas

Also Published As

Publication number Publication date
WO1996037232A1 (es) 1996-11-28
DE69634927T2 (de) 2008-05-15
US5843509A (en) 1998-12-01
CA2195881A1 (en) 1996-11-28
PT771566E (pt) 2006-08-31
DE69634927D1 (de) 2005-08-18
EP0771566A1 (en) 1997-05-07
CA2195881C (en) 2006-09-12
ES2093562B1 (es) 1997-07-01
EP0771566B1 (en) 2006-06-21
DK0771566T3 (da) 2006-10-23
ATE330636T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
ES2093562A1 (es) Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
Zimmer et al. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers
US5989535A (en) Polymeric bioadhesive emulsions and suspensions and methods of treatment
EP0995435B1 (en) Aqueous suspension preparations with excellent redispersibility
US5837226A (en) Ocular microsphere delivery system
US5585109A (en) Cosmetic delivery system for salicylic acid and process for preparation of same
US5935604A (en) Nasal drug delivery composition containing nicotine
EP0608353B1 (en) LOW pH AQUEOUS COSMETIC GEL CONTAINING NON-IONIC POLYACRYLAMIDE DERIVATIVES
JP3624418B2 (ja) リポソーム点眼液
WO2000009096B1 (en) Injectable formulations of nanoparticulate naproxen
CA2278541A1 (en) Pharmaceutical preparations and methods for their regional administration
AU4900996A (en) Compositions comprising nanoparticles of nsaid
Diepold et al. Distribution of poly-hexyl-2-cyano-[3-14C] acrylate nanoparticles in healthy and chronically inflamed rabbit eyes
JP2001502942A (ja) 皮膚電池化粧用組成物
IE831611L (en) Topical anti-inflammatory compositions
EP0463065B1 (en) Novel antiperspirant adduct compositions and process for making same
CA2147362C (en) Topical ophthalmic pharmaceutical vehicles
WO1998011874A1 (en) Pharmaceutical composition forming a gel
AU7040696A (en) Preparation of polymer powders which are redispersible in an aqueous medium
JP2001508026A (ja) ウォーターベースのメーキャップ組成物ならびにその調整方法
JPH07233045A (ja) 皮膚外用剤
JPH08510731A (ja) 治療使用のためのその場で生成するゲル
WO1992003123A1 (en) Liposome alternative bilayer formulations
JP3660639B2 (ja) 皮膚外用剤
JP3660660B2 (ja) 不溶性粉体、皮膚バリア機能回復粉体、肌荒れ防止・改善粉体及びそれを含む皮膚外用剤

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19961216

Kind code of ref document: A1

Effective date: 19961216

FD2A Announcement of lapse in spain

Effective date: 20180806